Applied Pharmaceutical Nanotechnology 2019
October 25, 2019
Pfizer
1 Portland Street
Cambridge, MA 02139
Plenary Speakers for APN 2019
![]() |
Greg Troiano, MSE, Vice President of Technology and Chief Engineer, Seer, Inc. Biomolecular Biosensors for Health Monitoring and Disease Detection - An Update |
|
![]() |
Ulrich von Andrian, M.D., Ph.D. Mallinckrodt Professor of Immunopathology, Harvard Medical School Using Nanomaterials to Communicate with the Immune System |
Confirmed Speakers for APN 2019
![]() |
Zohreh Amoozgar, PhD, Post Doctoral Research Fellow, Harvard Medical School at Massachusetts General Hospital Reprogramming the Tumor Microenvironment to Improve Immunotherapy |
|
![]() |
Gilles Besin, PhD, Sr. Director, Immunology, Moderna Therapeutics Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocyte to Distinct Antigenic Moieties |
|
![]() |
Zhaohua Richard Huang, PhD, Senior Director of Research and Development, L.E.A.F. Pharmaceuticals Case Studies on CMC and Regulatory Challenges of Liposomal Drug Development |
|
![]() |
Hakho Lee, Ph.D., Associate Professor, Harvard Medical School Promise of Liquid Biopsy for Cancer Management |
|
![]() |
Christopher Locher, Ph.D., CEO and Founder, Versatope Therapeutics Membrane Vesicles for Vaccine and Therapeutic Delivery |
|
![]() |
Shiladitya Sengupta, Ph.D., Associate Professor of Medicine, Harvard Medical School and Assistant Professor of Health Sciences and Technology, MIT Understanding Cancer Immune Interactions at the Nanoscale: Going beyond T cell immune checkpoints |
|
Young-Ho Song, Pfizer A Novel in situ Hydrophobic Ion Paring (HIP) Formulation Strategy for Clinical Product Selection of a Nanoparticle Drug Delivery System |
||
![]() |
Gokul Swaminathan, PhD, Associate Principal Scientist, Merck Exploratory Science Center, Merck Research Laboratories Novel Immuno-Modulatory Lipid Nanoparticle Formulations for Vaccines and Immuno-Oncology Applications |
|
![]() |
Shraddha Thakkar, PhD, Principal Investigator, U.S. FDA Title TBA |
Proposed Sessions for 2019:
Session I: Particle Technology : Early and Late Stage Technology
Session II: Impact of Biology and Immunology in Nanotechnology
Session III: Regulatory Aspects of Nanotechnology
Please Join our Linkedin Group